localization of radiolabeled platelets showed that hepatic uptake significantly decreased in the treated W/B F, mice, but not in nontreated W / B F, mice. To elucidate the effect of PDN on the reticulo-endothelial phagocytic activity in W / B F, mice, we studied in vivo clearance of IgG-sensitized, %I-labeled autologous erythrocytes. W/B F, mice treated with PDN showed a marked impairment of their ability t o clear these cells, although PDN had little effect on the number of splenic or hepatic macrophage Fcy receptors. These results and our previous findings of splenectomy suggest that PDN improves platelet counts not only by suppressing systemic reticulo-endothelial phagocytic function but also by reducing antibody production. o 1992 by The American Society of Hematology.
platelet-bindable serum antibodies (PBAs) with Our findings based on platelet transfer experiments using W/B F, mice strongly suggest that PAAs on the platelet surface play a crucial role in the destruction of platelets by systemic RES.14 In the present study, we show that the repeated injection of W/B F, mice with prednisolone (PDN) leads to a remarkable increase in platelet counts. We further attempt to clarify which factors are responsible for the increase in platelet counts by studying in vivo platelet kinetics using this animal model. We show here that prolonged P U S , decreased PAAs and PBAs, and impaired clearance of sensitized red blood cells (RBCs) are induced by PDN administration. This suggests that the increase in platelet counts induced by PDN is mediated by both the suppression of RES functions and the reduction of antibody production.
MATERIALS AND METHODS
BALB/c, BXSB, and NZW mice were originally purchased from Jackson Laboratories (Bar Harbor, ME). W/B F, mice (hybrids of NZW females and BXSB males) were raised under specific pathogen-free conditions in the animal facility of Kiwa Experimental Animal Laboratories (Wakayama, Japan).
Blood (20 pL) was diluted in a buffer containing ammonium oxalate (Unopette Kits, Becton Dickinson, Sunnyvale, CA). Platelets were counted using a hematocytometer under a phase-contrast microscope.
Each mouse was intraperitoneally (IP) injected daily for 4 weeks with PDN (Predonine; Shionogi Pharmaceutical Co, Osaka, Japan) (2 mg/kg in 0.1 mL of isotonic saline).
Control mice received the same volume of saline. No mice died during treatment, and all mice survived for more than 3 weeks after the end of treatment.
"'In-tropolone was used for the labeling of platelets. Details of the methods are described elsewhere." Recipient mice were injected intravenously with the radiolabeled platelets (approximately 185 KBq in 0.2 mL). Blood (15 pL) was then taken 1 minute, 30 minutes, 1 hour, 2 hours, 4 hours, 24 hours, and 48 hours after injection, and the radioactivity counted using a well-typed scintillation counter. The mean PLS was estimated by calculating the rate of platelet disappearance Mice.
Platelet counts.

Prednisolone treatment.
Platelet labeling and kinetics studies. where blood volume (mL) = body weight (g) x 0.078.16 Platelet turnover was calculated using the following formula":
Platelet Count ( x lo-'/pL) x 90 Platelet Lifespan (days) x Platelet Recovery (%) Turnover = For stable platelet counts, it is assumed that platelet turnover equals platelet production."
Mice were killed 72 hours after injection to determine the organ localization of the radiolabeled platelets. The liver, spleen, lungs, and bone marrow (femurs) were removed to determine the level of radioactivity in the organs.
We used a modified method of platelet suspension immunofluorescence test for PAAs and PBAs, as previously described." Briefly, platelet suspension was obtained from EDTA blood (50 pL) by differential centrifugation. After washing, the platelets were k e d with 1% paraformaldehyde. The platelets were resuspended in 100 pL of EDTA-phosphatebuffered saline (PBS) to a platelet count of 3 X l@/pL. They were then incubated with 5 pL of fluorescein isothiocyanate (FITC)-conjugated goat antimouse Ig (Becton Dickinson) for 30 minutes to determine PAAs. For the detection of PBAs, 100 pL of normal BALB/c platelets (3 x l@/pL) were incubated with 100 pL of serum (1:4 dilution) for 30 minutes at room temperature. FITCconjugated goat antimouse Ig was then added. After final washing, samples were analyzed on a FACScan (Becton Dickinson). For the quantification of PAAs and PBAs, we used modified methods of Lazarchick et al.I9 The intensity of fluorescence, expressed as the mean channel of the histogram, was calculated in each sample, and then compared with that of the control. A ratio of relative fluorescence (FR) was determined, where FR = (mean channel of sample)/(mean channel of control). The autofluorescence of the platelets (for PAAs) and the second antibody alone (for PBAs) were used as controls.
Clearance studies. Na, 5'Cr0, (37 MBq/mL) in sterile isotonic saline was obtained from Daiichi Radioisotope Co (Tokyo, Japan). Labeling and clearance studies were performed according to the methods of Shear et al.m Briefly, blood (0.5 mL) obtained from nontreated W/B F, mice in acid-citrate-dextrose (ACD) was washed three times in ACD-saline (pH 6.8). Three milliliters of washed erythrocytes (RBCs) (5.0 x 1O8/mL) was incubated with 3.7 MBq sodium chromium in a 37°C water bath for 45 minutes. The labeled RBCs were then washed three times in ACD-saline and resuspended in 108/mL of isotonic saline. Equal volumes of purified antimouse RBC IgG (rabbit) (Inter-Cell Technologies, Inc, Hopewell, NJ; 1:750 dilution) and 51Cr-labeled RBC suspension were incubated under constant agitation for 30 minutes at 37°C. After washing three times in ACD-saline, radiolabeled, IgG-coated RBCs were resuspended in isotonic saline (2 x 108/ mL). Recipient mice were injected intravenously with treated RBCs (0.2 mL) and blood (15 pL) was taken at 1,5,10,30,60, and 120 minutes. The samples were suspended in 1.0 mL of distilled water, and radioactivity counted as mentioned above. The number of cpm at 5 minutes after injection was taken as loo%, and the rate of disappearance of labeled RBCs from circulation calculated in each mouse.
PAAs and PBAs.
Macrophage Fcy receptor (FcyR) assay. Macrophage FcyR expression was assessed by the binding of 2.4G2 (rat monoclonal antibody against antimouse FcyII recepto?') according to the methods of Petroni et ai." Briefly, spleen mononuclear cell suspensions isolated from the density gradient were washed three times in 5 mmol/L EDTA-PBS with 0.1% sodium azide. Splenic macrophage-rich fractions were then obtained by the plastic dish method. For the isolation of hepatic macrophages, liver was minced and washed twice with Hanks' balanced salt solution (HBSS), then incubated at 37°C for 60 minutes with 5 mL of HBSS containing 2.5 mg of collagenase (type 11; Sigma Chemical Co, St Louis, MO) and 1.0 mg of trypsin inhibitor (type 1 4 ; Sigma). The resulting cell suspension was filtered by passing it through sterile cotton gauze and centrifuged three times at 6% for 1 minute to remove hepatocytes. The supernatant was washed three times with HBSS and resuspended with EDTA-PBS. This hepatic or splenic macrophage-rich fraction (more than 50% were morphologically identified as macrophage, 1 X 107/100 pL) was incubated with saturating concentrations of purified 2.462 or rat IgG at 4°C for 30 minutes. After washing three times in EDTA-PBS, the cells were then incubated with 50 pL of FITC-conjugated rabbit F(ab')* directed against rat Ig (Serotec Co, Oxford, UK; 1:100 dilution) for 30 minutes. After final washing, macrophages were sectioned with the scatter-gating method, and a total of 1 x 104 cells within the gate were analyzed using a FACScan. Data were expressed as FR (as described above).
Statistical analyses. The means of platelet counts, PLSs, and PAAs were compared using a paired or unpaired Student's t-test at the .05 significance level. 
RESULTS
Effect
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The control W/B F, mice, which were treated with isotonic saline alone, showed a slight decrease in platelet counts with age (Fig l) , which was similar to the platelet counts of nontreated W/B F, mice (data not shown); this decrease with age was considered to be a natural course of the disease. Table 1 shows the PLSs of each mouse before and after treatment. The P U S of male BALB/c (3 months) and female W/B F, (3 months) mice were 2.11 f 0.28 and 1.44 f 0.21 days, respectively, whereas those of male W/B F, (3 months) mice were significantly shortened (0.60 f 0.24 days). Four weeks after PDN treatment, a significant prolongation of P U S was observed (1.29 f 0.40 days), in contrast to controls (0.47 f 0.32 days; P < .Ol); values were also significantly prolonged in contrast to those before PDN treatment (0.60 f 0.24 days; P < .01). The effect of PDN treatment on platelet recovery and platelet turnover is also shown in Table 1 . The male W/B F, mice showed a significantly increased platelet turnover, in contrast to the male BALB/c and female W/B F, mice (P < .Ol), which showed no such increase. Four weeks after PDN treatment, a decreased turnover was observed in W/B F, mice (1,579 2 252 x lo3 platelets/p,L/d), in contrast to nontreated W/B F, mice (2,297 f 364; P < .05). Table 2 summarizes the uptake of "'In-labeled platelets by major organs 3 days after injection. The spleen and liver of male W/B F, mice were the main accumulation sites of labeled platelets; the mice showed mild hepato-splenomegaly. A slight but significant decrease in hepatic uptake was noted in PDN-treated W/B F, mice, in contrast to nontreated controls (P < .05, Table 2 ). Figure 2 shows the representative data regarding flow cytometric changes in PAA and PBA values of a single mouse. Four weeks after PDN treatment, a significant decrease both in PAA (FR, mean f SD) (before, 4.9 +-2.8; after, 2.4 f 0.8; n = 5, P < .05) and PBA values (before, 4.4 f 0.9; after, 2.2 f 0.8; n = 5, P < .01) was observed. The peak channel of fluorescence intensity of PAAs and PBAs on FACS analyses shifted to the left after PDN treatment (Fig 2C and D) , whereas that of the control W/B F, mice shifted to the right, suggesting that both PAA and PBA values increased (Fig 2A and B 
1).
Clearance of ZgG-coated RBCs. "Cr-labeled RBCs coated with IgG antibody were injected into 3-month-old W/B F, mice, and the fate of the cells then determined (Fig 3) . Nontreated W/B F, mice (n = 4) showed a rapid clearance of these cells, whereas W/B F, mice treated with PDN for 4 weeks (n = 4) showed a much lower clearance rate. At 2 hours, 35% f 12% (mean f SD) of the IgG-coated RBCs remained in the circulation in the treated group, compared with 11% f 6% in the controls (P < .05). Tr-labeled, nonsensitized RBCs were not removed from the circulation (Fig 3) .
Effect of PDN treatment on macrophage Fc yR expression.
To evaluate the effect of PDN on the FcyR number of splenic or hepatic macrophages, we analyzed the macrophage FcyR expression using the rat monoclonal antibody (2.462) that specifically binds to FcyR I1 on mouse macrophages. Table 3 shows the FcyR expression of W/B F, mice after 4 weeks of PDN treatment. Although the expression of FcyR on hepatic or splenic macrophages from PDN-treatment mice slightly decreased, no statistically significant change was found by FACS analyses, suggesting that PDN has little effect on the number of FcyRs.
DISCUSSION
A number of investigators have studied the effects of corticosteroids on experimentally induced hemolytic anemia or thrombocytopenia in animal~.8.~.~ In most experiments, heterologous antisera were injected directly in animals, and kinetics studies were then performed. These studies differed from ours in that they were not able to systematically examine the in vivo effects of PDN on autoantibody production, etc, because these animals do not spontaneously produce antiplatelet antibodies. In contrast, W/B F, mice spontaneously produce antiplatelet antibodies resulting in thrombocytopenia. We therefore consider the W/B F, mouse to be a useful animal model for the investigation of the mode of action of corticosteroids in ITP.
W/B F, mice are known to develop systemic lupus erythematosus-like diseases and show high levels of circulating immune complexes (CICS)."*~ It is therefore conceiv- For able that CICs are involved in thrombocytopenia in these mice. However, we think that the increased PAA levels are not due to the absorption of CICs because (1) murine platelets have no Fc recepto?; (2) other typical SLE-prone mice such as BXSB, MRL/lpr, and NZB/NZW F,, which show high CIC levels, have normal platelet countsz7."; (3) the sera from these mice do not bind to platelets of normal miceI3; and (4) purified F(ab'), fragments of W/B F, IgG can also bind to normal platelets (unpublished data).
In this study, we have shown that PDN leads to increased platelet counts and prolonged PLSs in W/B F, mice. Clearance studies using IgG-coated RBCs also showed a significant suppression of the ability to clear these cells. These observations suggest that one of the mechanisms of action of PDN is the suppression of the reticulo-endothelial phagocytic function. Consequently, PDN may modulate P U S and increase platelet counts. Furthermore, marked decreases in PAA and PBA values were noted after PDN treatment in W/B F, mice, suggesting that another mechanism of PDN is the reduction of autoantibody production. It remains uncertain which mechanism is the most important with regard to the increased platelet counts in these mice, although we think that for at least 2 weeks after the treatment, PDN may act by suppressing reticulo-endothelial phagocytic activity, rather than by reducing antibody production, as platelet counts increased extremely rapidly (within 2 weeks) without any significant changes in the PAA or PBA values.
Another possible effect of PDN on PAA and PBA values is impairment of the interaction between antibodies and antigens, resulting in decreased binding of antibodies to platelets. Although this is conceivable, it seems unlikely, because PDN cannot interfere with the binding of serum antiplatelet antibodies to platelets for long periods without any significant reduction in antibody production.
We have recently examined the effect of splenectomy on platelet kinetics in W/B F, mice, and found that platelet counts increased and P U S were prolonged, but normal levels were not reached even after splenectomy; splenectomy had little effect on either PAA or PBA values.'8 From these findings, we consider that the limited effect of splenectomy may be explained by the presence of the systemic RES other than the spleen. In the present study, PDN showed a greater therapeutic effect on platelet counts than splenectomy. It is therefore likely that PDN improves platelet counts not only by suppressing antibody production but also by blocking the systemic RES (including the spleen).
Recently, Gernsheimer et a1 showed that platelet production was impaired in some ITP patients." If this is the case, PDN may improve the platelet count by increasing platelet production. However, in nontreated W/B F, mice, increased platelet turnover (platelet production) was observed, and a relatively reduced platelet turnover was noted in PDN-treated W/B F, mice. These findings indicate that, in W/B F, mice, both platelet production and destruction For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From tMice were treated with isotonic saline for 4 weeks.
are accelerated, and that PDN may act by suppressing platelet destruction rather than by increasing platelet production.
The exact mechanism of PDN-induced suppression of the RES has not been fully defined. One interesting finding of our study on organ distribution is that PDN induces a relative decrease in hepatic uptake compared with nontreated controls, without a significant change in splenic uptake. These findings suggest that PDN may act by either directly suppressing the phagocytic activity of Kupffer cells or by modulating the hepatic blood flow. In either case, the present findings are consistent with our previous findings that the limited effect of splenectomy may be due to the presence of the systemic RES other than the spleen (probably the liver). We conclude that corticosteroids improve platelet counts in W/B F, mice not only by suppressing systemic reticuloendothelial phagocytic function but also by reducing autoantibody production, and that they have little effect on platelet production.
